Cingulate Q2 net loss $5.9M, cash $28.4M; CTx-1301 NDA resubmission progress, Prasco deal

Cingulate Inc.

Cash and cash equivalents $28.4M as of June 30, 2026, up from $11.0M at Dec 31, 2025; runway into mid-2027.
Q2 net loss $5.9M vs $5.0M YoY; six-month net loss $15.2M vs $8.8M; SG&A up 101.5% to $3.9M.
FDA CRL on June 1, 2026 for CTx-1301 NDA requested additional CMC info; no safety/efficacy concerns; resubmission planned.
U.S. Patent No. 12,653,791 issued June 16, 2026 covering CTx-1301, expires Dec 2042.
Signed exclusive distribution agreement with Prasco, LLC on July 21, 2026 for CTx-1301 launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.